期刊
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
卷 22, 期 -, 页码 122-132出版社
CELL PRESS
DOI: 10.1016/j.omtm.2021.05.014
关键词
-
资金
- NIH [HL130253]
- Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center [P50 HD 087351]
- Robert A. Welch Foundation [1-0025]
A study introduced an efficient gene-editing method using SaCas9 to correct the commonly affected exon 51 in DMD, which showed promising therapeutic effects in correcting DMD in a mouse model through a single AAV9 delivery system.
Duchenne muscular dystrophy (DMD), caused by mutations in the X-linked dystrophin gene, is a lethal neuromuscular disease. Correction of DMD mutations in animal models has been achieved by CRISPR/Cas9 genome editing using Strepto-coccus pyogenes Cas9 (SpCas9) delivered by adeno-associated virus (AAV). However, due to the limited viral packaging capacity of AAV, two AAV vectors are required to deliver the SpCas9 nuclease and its single guide RNA (sgRNA), impeding its therapeutic application. We devised an efficient single-cut gene-editing method using a compact Staphylococcus aureus Cas9 (SaCas9) to restore the open reading frame of exon 51, the most commonly affected out-of-frame exon in DMD. Editing of exon 51 in cardiomyocytes derived from human induced pluripotent stem cells revealed a strong preference for exon reframing via a two-nucleotide deletion. We adapted this system to express SaCas9 and sgRNA from a single AAV9 vector. Systemic delivery of this All-In-One AAV9 system restored dystrophin expression and improved muscle contractility in a mouse model of DMD with exon 50 deletion. These findings demonstrate the effectiveness of CRISPR/SaCas9 delivered by a consolidated AAV delivery system in the correction of DMD in vivo, representing a promising therapeutic approach to correct the genetic causes of DMD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据